Amplia Therapeutics: Granted $2.1 million R&D cash flow loan

Amplia Therapeutics Granted $2.1 million R&D cash flow loan

  • Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan
  • The $2.1 million will be awarded in two tranches: $1.3m in December this year and $0.8 million in the quarter ending March 31, 2022
  • The company says it will use funds to increase work on its second Focal Adhesion Kinase (FAK) inhibitor, AMP886
  • This will allow Amplia to evaluate new therapeutic opportunities and prepare preclinical activates designed to support future clinical trials of AMP886
  • AmpliaTherapeutics is up 2.9 per cent, trading at 18 cents at 12:40 pm AEDT
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Experian Launches Credit Score App in ChatGPT, Enhancing Financial Access

New tool enables users to check credit scores effortlessly via ChatGPT.Highlights: Experian's app allows users to check credit...

US Senate Passes Bill Banning Issuance of CBDCs

Legislation aims to restrict the development of digital currencies by the Federal Reserve.Highlights: The US Senate approved a...

Truist Expands Open Banking Offerings with Plaid Partnership

Collaboration aims to enhance customer access to financial services.Highlights: Truist collaborates with Plaid for open banking expansion.The partnership...

UK’s National Fraud Database Reports 444,000 Fraud Cases in 2025

Cifas reveals a significant rise in reported fraud incidents across the UK.Highlights: Cifas reported 444,000 fraud cases in...